Although IM has been shown to inhibit BCR-ABL activity in CD34+ chronic phase CML cells, only a mild increase in apoptosis was demonstrated in these cells [33]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.